Clozapine에 의한 심근염 1예
A Case of Clozapine-Induced Myocarditis
1
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Clozapine is an atypical antipsychotic agent that is more effective than the typical neuroleptics in the treatment of refractory schizophrenia. Recently, there has been an increased recognition of the association of clozapine with myocarditis and cardiomyopathy. Commonly used diagnostic tests have limited sensitivity in diagnosing this potentially life-threatening complication. Here we report a case of 36-year-old male patient who developed fever, tachycardia, and dyspnea after introduction of clozapine. By clinical evaluation and laboratory test we diagnosed the patient with myocarditis and treated him successfully. To our knowledge this is the first case report of clozapine-induced myocarditis in Korea
Abstract
Clozapine is an atypical antipsychotic agent that is more effective than the typical neuroleptics in the treatment of refractory schizophrenia. Recently, there has been an increased recognition of the association of clozapine with myocarditis and cardiomyopathy. Commonly used diagnostic tests have limited sensitivity in diagnosing this potentially life-threatening complication. Here we report a case of 36-year-old male patient who developed fever, tachycardia, and dyspnea after introduction of clozapine. By clinical evaluation and laboratory test we diagnosed the patient with myocarditis and treated him successfully. To our knowledge this is the first case report of clozapine-induced myocarditis in Korea
참고문헌 (33)
- Owens DG, "Adverse effects of antipsychotic agents. Do newer agents offer advantages?", Drugs, 51, pp.895~930 (1996)
- Conley RR, "Optimizing treatment with clozapine", J Clin Psychiatry, 59(Suppl 3), pp.44~48 (1998)
- McElroy SL, "Clozapine in the treatment of psychotic mood disorders, schizoaffective disorder, and schizophrenia", J Clin Psychiatry, 52, pp.411~414 (1991)
- Suppes T, "Clozapine in the treatment of dysphoric mania", Biol Psychiatry, 32, pp.270~280 (1992)
- Meltzer HY, "Reduction of suicidality during clozapine treatment of neuroleptic-resistant schizophrenia: impact on riskbenefit assessment", Am J Psychiatry, 152, pp.183~190 (1995)
- Volavka J, "Clozapine effects on hostility and aggression in schizophrenia", J Clin Psychopharmacol, 13, pp.287~289 (1993)
- Krakowski MI, "Atypical antipsychotic agents in the treatment of violent patients with schizophrenia and schizoaffective disorder", Arch Gen Psychiatry, 63, pp.622~629 (2006)
- Weintraub D, "Presentation and management of psychosis in Parkinson’s disease and dementia with Lewy bodies", Am J Psychiatry, 164, pp.1491~1498 (2007)
- Baldessarini RJ, "Clozapine. A novel antipsychotic agent", N Engl J Med, 324, pp.746~754 (1991)
- Alvir JM, "Clozapine-induced agranulocytosis. Incidence and risk factors in the United States", N Engl J Med, 329, pp.162~167 (1993)
- 노성원, "Clozapine과 연관된 확장성 심근병증", 신경정신의학, 44(1), pp.125~128 (2005), 대한신경정신의학회
- Young CR, "Management of the adverse effects of clozapine", Schizophr Bull, 24, pp.381~390 (1998)
- Mackin P, "Cardiac side effects of psychiatric drugs", Hum Psychopharmacol, 23(Suppl 1), pp.3~14 (2008)
- Hägg S, "Myocarditis related to clozapine treatment", J Clin Psychopharmacol, 21, pp.382~388 (2001)
- Kilian JG, "Myocarditis and cardiomyopathy associated with clozapine", Lancet, 354, pp.1841~1845 (1999)
- La Grenade L, "Myocarditis and cardiomyopathy associated with clozapine use in the United States", N Engl J Med, 345, pp.224~225 (2001)
- Commitee on safety of medicines, "Myocarditis with antipsychotics: recent cases with clozapine (clozaril)", Current Problems in Pharmacovigiliance, 19, pp.9~10 (1993)
- Coulter DM, "Antipsychotic drugs and heart muscle disorder in international pharmacovigilance: data mining study", BMJ, 322, pp.1207~1209 (2001)
- Novartis, "Dear health care provider: myocarditis added to boxed warning", ~ (2002)
- Haas SJ, "Clozapine-associated myocarditis: a review of 116 cases of suspected myocarditis associated with the use of clozapine in Australia during 1993-2003", Drug Saf, 30, pp.47~57 (2007)
- Calabrese F, "Myocarditis and inflammatory cardiomyopathy: microbiological and molecular biological aspects", Cardiovasc Res, 60, pp.11~25 (2003)
- Ruetsch O, "Psychotropic drugs induced weight gain: a review of the literature concerning epidemiological data, mechanisms and management", Encephale, 31(4 Pt 1), pp.507~516 (2005)
- Razminia M, "Clozapine induced myopericarditis: early recognition improves clinical outcome", Am J Ther, 13, pp.274~276 (2006)
- Feldman AM, "Myocarditis", N Engl J Med, 343, pp.1388~1398 (2000)
- Tham JC, "Clozapine-induced fevers and 1-year clozapine discontinuation rate", J Clin Psychiatry, 63, pp.880~884 (2002)
- Kim Y, "Clinical use of clozapine: 89 questions and answers", pp.167~169 (2009), Seoul National University Press
- Pollmächer T, "On the clinical relevance of clozapine-triggered release of cytokines and soluble cytokine-receptors", Fortschr Neurol Psychiatr, 69(Suppl 2), pp.S65~S74 (2001)
- Burian J, "Myocarditis: the immunologist’s view on pathogenesis and treatment", Swiss Med Wkly, 135, pp.359~364 (2005)
- Vaddadi KS, "Low blood selenium concentrations in schizophrenic patients on clozapine", Br J Clin Pharmacol, 55, pp.307~309 (2003)
- Hill GR, "Clozapine and myocarditis: a case series from the New Zealand Intensive Medicines Monitoring Programme", N Z Med J, 121, pp.68~75 (2008)
- Dukes MN, "The importance of adverse reactions in drug regulation", Drug Saf, 5, pp.3~6 (1990)
- Wooltorton E, "Antipsychotic clozapine (Clozaril): myocarditis and cardiovascular toxicity", CMAJ, 166, pp.1185~1186 (2002)
- Degner D, "Myocarditis associated with clozapine treatment", Aust N Z J Psychiatry, 34, pp.880~ (2000)